These two compounds seem to specifically target one key enzyme that makes cholesterol, without messing with the other parts of the process — at least in lab tests.

What we've found so far suggests that ML-236A and ML-236B may selectively inhibit HMG-CoA reductase without affecting other enzymes involved in cholesterol synthesis. Our current analysis is based on limited evidence, but what we’ve reviewed leans toward this specificity. We analyzed the available research and found that these compounds appear to target HMG-CoA reductase, a key enzyme in the cholesterol production pathway [1]. This enzyme plays a central role in the early stages of cholesterol synthesis, and inhibiting it can reduce overall cholesterol levels. According to the evidence we’ve reviewed, there is no indication that ML-236A and ML-236B interfere with other enzymes in the same pathway—at least under laboratory test conditions [1]. The data we have so far points to a focused action on this one enzyme, which could mean fewer disruptions to related metabolic processes. However, our analysis is based on a small body of evidence—just one assertion from lab-based studies. We don’t yet have data from human trials or long-term observations, and we can’t be certain how these compounds behave in more complex biological systems. Lab results don’t always translate directly to effects in the body. Based on what we've reviewed so far, the evidence leans toward selective inhibition of HMG-CoA reductase by ML-236A and ML-236B. Still, we don’t have enough evidence to say how this effect holds up in real-world conditions or over time. Practical takeaway: These compounds may zero in on one key cholesterol-making enzyme without disturbing others—based on early lab tests. But we need more data before we can say how this plays out in people.